LANDSVIRKJUN
14.12.2016 12:02:27 CET | Business Wire | Press release
Landsvirkjun, the National Power Company of Iceland, and Advania have signed a power purchase agreement for the supply of energy to Advania’s Fitjar data centre in the southwest of Iceland. The energy will be supplied by the end of 2016 according to the agreement, which will enable Advania to continue to expand their data center operations.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161214005221/en/
Landsvirkjun will supply the energy through its current power station network. The company has supported the growth of the data center industry in recent years in Iceland by offering energy from 100% renewable resources.
Hörður Arnarson, CEO of Landsvirkjun:
"Advania is a welcome addition to Landsvirkjun’s client base. The conditions in Iceland are ideal for data center operations and Landsvirkjun has in recent years actively promoted Iceland as a preferred location for data centers. The successful growth of Advania and other data centers in Iceland is based on favourable, long-term, secure energy contracts, a competitive environment and the cooperation of stakeholders within the industry in Iceland."
Gestur G. Gestsson, CEO of Advania:
"The scope of Advania’s operations, within the data center market, has grown tremendously in recent years and large-scale projects are in the pipeline in the coming months. Access to energy is a key factor in the operation of data centers and we are therefore greatly pleased by this agreement with Landsvirkjun. We believe That Landsvirkjun will strengthen our ability to service more global clients in the future. "
Advania is a leading Nordic IT company with operations in Iceland, Sweden and Norway. The company has around 1000 employees, working from 20 different stations of operation. Advania operates the Steinhella Data Center in Hafnarfjordur and the Fitjar Data Center in Reykjanesbær. The agreement will allow the company to further grow its data center operations and add to its client base.
Landsvirkjun generates 100% of its power from renewable resources. The company owns and operates 16 power stations, including 14 hydropower stations and two geothermal stations as well as two wind turbines. Landsvirkjun is currently constructing a geothermal power station at Þeistareykir in the northeast of Iceland and is also expanding its hydropower station network in Búrfell, in the south of Iceland.
The offering of favourable long-term power purchase agreements makes Iceland a competitive location to set up data centers and the stable, cold climate of the country is particularly suitable for data center operations. Redundant submarine fibre cable system provides the reliable connectivity required by demanding international data centers.
Landsvirkjun has actively promoted Iceland to the responsible parties for determining future locations of data centers. The Company's website contains information on the benefits of Iceland in this regard:
http://www.landsvirkjun.com/datacenters
View source version on businesswire.com: http://www.businesswire.com/news/home/20161214005221/en/
Contact:
Landsvirkjun
Magnús Þór Gylfason, +354 515 9000
Director of
Corporate Communications
Magnus.Thor.Gylfason@landsvirkjun.is
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom